Karyopharm Therapeutics (KPTI) Change in Accured Expenses (2012 - 2025)

Karyopharm Therapeutics (KPTI) has 14 years of Change in Accured Expenses data on file, last reported at $1.4 million in Q4 2025.

• Quarterly Change in Accured Expenses fell 77.67% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.1 million (up 353.77% YoY) and the FY2025 annual result came in at $19.1 million, up 353.77% from the prior year.
• Change in Accured Expenses retreated to $1.4 million in Q4 2025, from $9.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.1 million in Q3 2021 to a low of -$9.4 million in Q1 2023.
• A 5-year average of $1.7 million and a median of $2.3 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 373.51% — and 2025, when it jumped 14957.89%.
• Tracing KPTI's Change in Accured Expenses over 5 years: stood at $3.7 million in 2021, then plunged by 43.34% to $2.1 million in 2022, then soared by 129.16% to $4.8 million in 2023, then jumped by 35.08% to $6.5 million in 2024, then sank by 77.67% to $1.4 million in 2025.
• The last three Change in Accured Expenses figures came in at $1.4 million (Q4 2025), $9.5 million (Q3 2025), and $8.6 million (Q2 2025), per Business Quant data.